Statins less dangerous than thought for liver patients

November 24, 2010

Long-term use of statins, a drug widely prescribed to prevent artery-blocking cholesterol, is less risky than thought for patients with a common form of liver disease, according to a study published on Wednesday by The Lancet.

Statins work by blocking a liver enzyme that makes fatty molecules which line arterial walls and boost the danger of heart disease and strokes.

Doctors commonly choose not to prescribe these drugs to people with high levels of a type of liver enzyme which is often a telltale of non-alcoholic , or NAFLD.

Few studies have until now been carried out into the benefits or risks of this policy, and the probes have been small and short-term.

In the biggest and longest investigation of its kind, doctors in Greece enrolled 437 patients who had abnormal liver function tests and were believed to have NAFLD.

Of these, 227 of whom were treated with a statin, while the others were not treated.

Over the three-year duration of the study, 10 percent of patients in the statin group had a heart attack or a stroke, while in the non-statin group, this was 20 percent. The benefit for the statin group was a relative risk reduction of more than two-thirds.

Bouts of liver-related sickness were equal in both groups, indicating no adverse affects on the liver from taking .

The study was led by Vasilis Athyros from the Hippokration University Hospital in Thessaloniki, Greece and Dimitri Mikhailidis from University College London, London.

Commenting on the study, Ted Bader from the University of Oklahoma Health Sciences Center said the findings demonstrated emphatically that many patients with liver disease had been wrongly denied statins for for too long.

"Most physicians believe that statins cause liver disease because of the language of package inserts. Drug companies should be encouraged to request the deletion of this point from the insert," he said.

Statins have been dubbed "the aspirin of the 21st century" for their perceived benefits in cardiovascular health and relatively few side effects. Worldwide sales total more than 20 billion dollars annually.

A study published last week cautioned against over-prescribing, saying that among healthy adults, only those with measurable buildup of artery-hardening calcium would significantly benefit.

The six-year study found that 75 percent of all heart attacks, strokes or heart-related deaths occurred in the 25 percent of participants who had the highest calcium buildup in their blood vessels.

The 47 percent of participants who had no detectable levels of calcium buildup meanwhile suffered just five percent of heart disease-related events, meaning the therapy would have offered little protection.

Related Stories

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.